Tumor News and Research

RSS

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

Patients with advanced chronic lymphocytic leukemia often receive donor transplants that effectively "reboot" their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there is a high rate of relapse in these patients, and the transplanted immune cells may also harm normal tissues, causing graft-versus-host disease.

7 Aug 2013

Combining drugs that target AXL and ErbB receptors could offer better way to fight tumors

Cancer drugs known as ErbB inhibitors have shown great success in treating many patients with lung, breast, colon and other types of cancer. However, ErbB drug resistance means that many other patients do not respond, and even among those who do, tumors commonly come back.

7 Aug 2013

NCI awards LTR $1.3M to continue its work in SEER cancer registry

The Louisiana Tumor Registry (LTR) at the LSU Health Sciences Center New Orleans School of Public Health has been awarded a $1.3 million contract by the National Cancer Institute to continue its work as a SEER (Surveillance, Epidemiology and End Results) Program-designated cancer registry.

7 Aug 2013

UCLA researchers combine cellular and gene therapies to develop treatment for breast cancer

Researchers at UCLA's Jonsson Comprehensive Cancer Center have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that has spread to a patient's brain.

7 Aug 2013

TTY BIOPHARM receives Outstanding Company of the Year award

TTY BIOPHARM was awarded "Outstanding Company of the Year", the highest award given at the Bio Taiwan 2013 Exhibition. At the opening ceremony on July 18, Rong-Jing Lin, Chairman and General Manager of TTY BIOPHARM, received the prize from Ma Ying-jeou, President of Taiwan.

6 Aug 2013

Study reveals nearly 40% of tumors are caused by viruses

The results of a large-scale analysis of the association between DNA viruses and human malignancies suggest that many of the most common cancers are not associated with DNA viruses.

6 Aug 2013

Tumor cell vaccination has potential to enhance anti-tumor responses following allo-HSCT

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that most often affects older adults. CLL responds to bone marrow stem cell transplantation (allo-HSCT); however, the rate of relapse for CLL remains relatively high.

6 Aug 2013

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

A team of scientists, led by Napoleone Ferrara, MD, has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.

6 Aug 2013

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common-and most aggressive-form of brain cancer in adults. The study was published August 5, 2013, in Nature Genetics.

6 Aug 2013

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

...

6 Aug 2013

Bayer Collaboration Could Net $540M+ For Compugen

...

6 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

Compugen Ltd. announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators.

5 Aug 2013

Affymetrix introduces new OncoScan FFPE Assay Kit

Affymetrix, Inc. announced the launch of the new OncoScan™ FFPE Assay Kit, a whole-genome copy number assay for highly degraded FFPE solid tumor samples, at the Cancer Cytogenomics Microarray Consortium conference being held in Chicago this week.

5 Aug 2013

Scientists discover way to target immune system to shrink tumors in mice

St. Jude Children's Research Hospital scientists have discovered a way to target the immune system to shrink or eliminate tumors in mice without causing autoimmune problems. Researchers also found evidence that the same mechanism may operate in humans. The study was published today in the advance online edition of Nature.

5 Aug 2013

Atossa Genetics: Many American women still not aware of breast cancer risk

Virtually all American women are aware that the pink ribbon is the symbol of breast cancer awareness. Despite this near-universal recognition, it is still a sad fact that plenty of women do not truly appreciate the extent to which they are at risk for breast cancer.

3 Aug 2013

Plymouth researcher awarded Young Investigator Award by Children's Tumor Foundation

Dr. Lu Zhou, a member of a team of researchers at Plymouth University Peninsula Schools of Medicine and Dentistry whose area of expertise is brain tumours, has been awarded a fellowship by the Children's Tumor Foundation.

3 Aug 2013

Castle Biosciences to present DecisionDx-Melanoma test data at Summer Academy Meeting of AAD

Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the Summer Academy Meeting of the American Academy of Dermatology. The validation data confirm previous studies showing that the gene expression profile test is a strong independent predictor for classifying which Stage I or II non-metastatic cutaneous melanoma patients will likely recur.

2 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Cancer biomarker tests undervalued by doctors and patients, authors say

There's a major roadblock to creating personalized cancer care. Doctors need a way to target treatments to patients most likely to benefit and avoid treating those who will not. Tumor biomarker tests can help do this.

2 Aug 2013

Tumor News and Research

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

Combining drugs that target AXL and ErbB receptors could offer better way to fight tumors

NCI awards LTR $1.3M to continue its work in SEER cancer registry

UCLA researchers combine cellular and gene therapies to develop treatment for breast cancer

TTY BIOPHARM receives Outstanding Company of the Year award

Study reveals nearly 40% of tumors are caused by viruses

Tumor cell vaccination has potential to enhance anti-tumor responses following allo-HSCT

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

Bayer Collaboration Could Net $540M+ For Compugen

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

Affymetrix introduces new OncoScan FFPE Assay Kit

Scientists discover way to target immune system to shrink tumors in mice

Atossa Genetics: Many American women still not aware of breast cancer risk

Plymouth researcher awarded Young Investigator Award by Children's Tumor Foundation

Castle Biosciences to present DecisionDx-Melanoma test data at Summer Academy Meeting of AAD

ImmunoGen reports net loss of $21.9 million in Q4 2013

Cancer biomarker tests undervalued by doctors and patients, authors say

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News